C4 Therapeutics (CCCC) Non-Current Debt (2020 - 2023)

C4 Therapeutics has reported Non-Current Debt for 4 years, with the latest figure at $8.6 million in Q1 2023.

• For the quarter ending Q1 2023, Non-Current Debt fell 15.43% year-over-year to $8.6 million; the trailing twelve-month figure through Mar 2023 stood at $8.6 million (down 15.43% YoY), and the FY2022 full-year result was $9.2 million, down 14.61% from the prior year.
• Non-Current Debt for Q1 2023 stood at $8.6 million, down from $9.2 million in the prior quarter.
• The five-year high for Non-Current Debt was $10.8 million in Q4 2021, with the low at $8.6 million in Q1 2023.
• Average Non-Current Debt over 4 years is $9.9 million, with a median of $10.2 million recorded in 2022.
• Year-over-year, Non-Current Debt rose 7.2% in 2021 and slipped 15.43% in 2023.
• Tracing CCCC's Non-Current Debt over 4 years: stood at $10.1 million in 2020, then increased by 7.12% to $10.8 million in 2021, then retreated by 14.61% to $9.2 million in 2022, then fell by 6.24% to $8.6 million in 2023.
• The last three Non-Current Debt figures came in at $8.6 million (Q1 2023), $9.2 million (Q4 2022), and $9.1 million (Q3 2022), per Business Quant data.

Peer Comparison